NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL
June 04 2019 - 2:00AM
NANOBIOTIX APPOINTS NEW CHIEF MEDICAL
OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET
APPROVAL
- Biopharmaceutical veteran Edwina Baskin-Bey, M.D.,
joins Nanobiotix as its new Chief Medical Officer
(CMO)
- Dr. Baskin-Bey will leverage her expertise in medical
strategy and late-stage clinical development to help accelerate the
company’s strategic objectives
- Dr. Baskin-Bey succeeds Elsa Borghi, M.D., who will
remain focused on the early development of innovative products at
Nanobiotix
“Dr.
Baskin-Bey has built an impressive career and she is joining us at
a critical time. As we advance development of NBTXR3 in multiple
solid tumor indications and in combination with checkpoint
inhibitors, Dr. Baskin-Bey’s breadth and depth of experience align
perfectly with our strategic leadership needs. To date, Dr. Borghi
has been instrumental in bringing our lead product to European
market approval. I am excited that she will continue to create and
develop new innovative approaches for Nanobiotix.” – Laurent Levy,
CEO of Nanobiotix
“It is an honor and a privilege to join
Nanobiotix. I am thrilled by the opportunity to lead a dedicated
team that operates on the cutting edge of nanophysics to develop
unique treatment solutions and improve patient outcomes. My
experience in global oncology product development, surgery and
radiation should serve to help us grow and to accelerate our global
clinical programs.” – Dr. Edwina Baskin-Bey, CMO of Nanobiotix
Paris, France and Cambridge,
Massachusetts, USA, June 4, 2019 –
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage
nanomedicine company pioneering new approaches to the treatment of
cancer, today announced it has appointed Edwina Baskin-Bey, M.D. as
its new CMO.
Dr. Baskin-Bey brings over 18 years of oncology
clinical development and basic science experience in academia and
industry, most recently serving as CMO of North Carolina-based
oncology start-up, Innocrin Pharmaceuticals. As a member of the
Executive Team at Innocrin, Dr. Baskin-Bey led development and
implementation of the overall clinical and corporate strategy from
phase I to phase III. She was responsible for the Medical,
Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics,
and Data Management functions.
Dr. Baskin-Bey joined Innocrin from Janssen
Oncology of Johnson & Johnson, where she was charged with
leading both early- and late-stage oncology global development
programs for in-licensed products from Aragon and Tesaro,
apalutamide and niraparib. Previously, she worked for more than six
years at Astellas Pharma. At Astellas, BV, Netherlands
Headquarters, Dr. Baskin-Bey, was responsible for several
early-stage oncology programs, most notably, she co-led with the
alliance partner, Medivation, the global development strategy for
the in-licensed product enzalutamide, leading to FDA approval, EMA
approval, and label expansions. Also while at Astellas, she served
at the UK Headquarters as head of European Medical Affairs, where
she was responsible for the launch of enzalutamide in Europe.
Dr. Baskin-Bey currently serves as an
independent board member for Catalyst Clinical Research, LLC, in
North Carolina. Dr. Baskin-Bey obtained her bachelor’s degree from
Hunter College in New York, and earned her medical degree at Mount
Sinai/New York University (NYU) School of Medicine. She trained in
general surgery and oncology for seven years at The Mayo Clinic in
Rochester, MN, and in basic science research principles at the
National Institute of Health (NIH).
Dr. Baskin-Bey succeeds accomplished Nanobiotix
CMO, Elsa Borghi, M.D. Dr. Borghi will remain with the company in a
key leadership role focused on early development and
innovation.
-Ends-
About
NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading,
clinical-stage nanomedicine company pioneering new approaches to
significantly change patient outcomes by bringing nanophysics to
the heart of the cell.
The Nanobiotix philosophy is rooted in designing
pioneering, physical-based approaches to bring highly effective and
generalized solutions to address unmet medical needs and
challenges.
Nanobiotix’s first-in-class, proprietary lead
technology, NBTXR3, aims to expand radiotherapy benefits for
millions of cancer patients. Nanobiotix’s Immuno-Oncology program
has the potential to bring a new dimension to cancer
immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company’s headquarters are in Paris, France, with a
U.S. affiliate in Cambridge, MA, and European affiliates in Spain
and Germany.
Contact
Nanobiotix |
Communications Department+33 (0)1 40 26 07
55+1 (617) 852-4835contact@nanobiotix.com |
Investor Relations
Department+33 (0)1 79 97 29 99+1 (646)
241-4400investors@nanobiotix.com |
Media relations |
France - Springbok
ConsultantsMarina Rosoff+33 (0)6 71 58 00
34marina@springbok.fr |
|
United States –
RooneyPartners Marion Janic +1
(212) 223-4017mjanic@rooneyco.com |
|
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business,
including its prospects and product candidate development. Such
forward-looking statements are based on assumptions that Nanobiotix
considers to be reasonable. However, there can be no assurance that
the estimates contained in such forward-looking statements will be
verified, which estimates are subject to numerous risks including
the risks set forth in the reference document of Nanobiotix
registered with the French Financial Markets Authority (Autorité
des Marchés Financiers) under number R.19-018 on April 30, 2019 (a
copy of which is available on www.nanobiotix.com) and to the
development of economic conditions, financial markets and the
markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements.
- PR_CMO_Edwina_Baskin-Bey_Announcement
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Aug 2023 to Aug 2024